BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//KESHO - ECPv6.15.20//NONSGML v1.0//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
X-ORIGINAL-URL:https://kesho-kenya.org
X-WR-CALDESC:Events for KESHO
REFRESH-INTERVAL;VALUE=DURATION:PT1H
X-Robots-Tag:noindex
X-PUBLISHED-TTL:PT1H
BEGIN:VTIMEZONE
TZID:Africa/Nairobi
BEGIN:STANDARD
TZOFFSETFROM:+0300
TZOFFSETTO:+0300
TZNAME:EAT
DTSTART:20240101T000000
END:STANDARD
END:VTIMEZONE
BEGIN:VEVENT
DTSTART;TZID=Africa/Nairobi:20250515T190000
DTEND;TZID=Africa/Nairobi:20250515T203000
DTSTAMP:20260423T225724
CREATED:20250414T200633Z
LAST-MODIFIED:20250622T142308Z
UID:24390-1747335600-1747341000@kesho-kenya.org
SUMMARY:Bladder Cancer
DESCRIPTION:Moderator: Roselyne A. Okumu \nSpeakers & Topics: \n\nDr Melissa Reimers: Updates in the Management of Advanced Bladder Cancer\nProf Peter Mungai: Superficial Bladder Cancer Management\n\nManagement of Non-Muscle-Invasive Bladder Cancer (NMIBC) \n– NMIBC represents ~75% of new bladder cancer cases\, typically presenting with painless hematuria.\n– Diagnosis: Cystoscopy and TURBT; blue light cystoscopy improves detection.\n– Risk-based treatment approach:\n• Low/intermediate-risk: single post-op intravesical chemo (mitomycin C/gemcitabine)\n• High-risk: 6-week BCG induction ± maintenance\n– BCG-unresponsive NMIBC: radical cystectomy or emerging therapies.\n– Promising bladder-sparing agents: TAR-200 (gemcitabine) and TAR-210 (erdafitinib).\n– Trials (MoonRISe-3\, SunRISe-5) show >80% DFS in high-risk patients. \nUpdates in Advanced and Metastatic Bladder Cancer \n– Bladder cancer is the 4th most common male cancer globally.\n– Molecular profiling is critical: test for FGFR3 and HER2.\n– 1st-line standard: Enfortumab vedotin + Pembrolizumab (EV-302/KEYNOTE-A39).\n– Platinum-eligible: Cis/gem ± nivolumab; Carb/gem → Avelumab maintenance.\n– 2nd/3rd-line: Erdafitinib (FGFR+)\, T-DXd (HER2+).\n– Novel ADCs (Enfortumab\, Sacituzumab) offer superior outcomes to chemo.\n– Trial enrolment is encouraged for all patients. \nKey Clinical Takeaways \n– Intravesical innovation is changing NMIBC treatment beyond BCG.\n– Biomarker-driven therapy is now essential for managing advanced bladder cancer.\n– Routine molecular testing is critical for individualized care
URL:https://kesho-kenya.org/event/bladder-cancer/
CATEGORIES:CME 2025,Continuing Medical Education (CME)
ATTACH;FMTTYPE=image/jpeg:https://kesho-kenya.org/wp-content/uploads/2025/04/Bladder-Cancer.jpg
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=Africa/Nairobi:20250508T190000
DTEND;TZID=Africa/Nairobi:20250508T203000
DTSTAMP:20260423T225724
CREATED:20250414T200448Z
LAST-MODIFIED:20250622T144009Z
UID:24388-1746730800-1746736200@kesho-kenya.org
SUMMARY:Management of Indolent Lymphomas
DESCRIPTION:[vc_row][vc_column][vc_column_text]Moderator: Prof Nicholas Otieno Abinya \nSpeakers & Topics: \n\nDr Samson Mutanda: Practical Approaches in Clinical Case‑Driven Exploration\nProf Shahin Sayed: Histopathology & Low‑Grade Lymphomas\nDr Matilda Ongondi: CT Treatment Algorithm – A Practical Approach\n\nDr. Samson Mutanda – presented case-based exploration of CLL management in Kenyan settings.\n– Key clinical points:\n• CLL is heterogeneous and often indolent; many patients start with watchful waiting.\n• Symptomatic cytopenias and disease progression warrant treatment.\n• Therapy included bendamustine\, rituximab\, venetoclax\, and novel agents like ibrutinib.\n– Highlighted diagnostic limitations due to access to FISH\, molecular testing\, and cost of targeted therapies.\n– Underscored importance of tailored care\, especially in young patients and those with co-morbidities. \nDr. Matilda Ongondi – Provided a clinical introduction to indolent lymphomas\, which are slow-growing B-cell neoplasms such as CLL/SLL\, follicular lymphoma\, and MZL.\n– Emphasized the necessity for clinical vigilance and long-term monitoring.\n– Stressed the need for diagnostic precision\, the role of immunophenotyping\, and the heterogeneity of clinical presentations.\n– Highlighted treatment considerations: watchful waiting\, targeted therapy\, and challenges in resource-limited settings. \nProf. Shahin Sayed – Reviewed WHO-HEM5 classification of indolent lymphomas\, emphasizing pathology-driven subtypes.\n– Covered key immunophenotypic markers: CD5\, CD23\, LEF1\, BCL2\, Cyclin D1\, etc.\n– Presented rare pediatric and adolescent cases\, illustrating diagnostic complexity and variability.\n– Detailed histologic signs of aggressive transformation (e.g. high Ki-67\, prolymphocytic features).\n– Outlined molecular diagnostics: del(11q\, 13q\, 17p)\, TP53 mutations\, IGHV SHM – all important for prognosis and treatment.\n– Discussed evolving terminology: classic FL\, follicular lymphoma with uncommon features (uFL)\, and follicular large cell lymphoma.[/vc_column_text][/vc_column][/vc_row]
URL:https://kesho-kenya.org/event/management-of-indolent-lymphomas/
CATEGORIES:CME 2025,Continuing Medical Education (CME)
ATTACH;FMTTYPE=image/jpeg:https://kesho-kenya.org/wp-content/uploads/2025/04/IMG-20250505-WA0000-e1746479789592.jpg
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=Africa/Nairobi:20250424T190000
DTEND;TZID=Africa/Nairobi:20250424T203000
DTSTAMP:20260423T225724
CREATED:20250414T200348Z
LAST-MODIFIED:20250622T144124Z
UID:24386-1745521200-1745526600@kesho-kenya.org
SUMMARY:Advanced Ovarian Cancer
DESCRIPTION:Moderator: Prof Rose J. Kosgei \nSpeakers & Topics: \n\nProf Omenge Orang’o: Management of Epithelial Ovarian Cancer\nDr Peter Oyiro: PARP Inhibitors in Ovarian Cancer\nDr Charles Muteshi: Fertility Preservation in Ovarian Cancer\n\nEpidemiology and Diagnosis (Prof. Omenge Oran’go) \n– Ovarian cancer remains a significant cause of cancer mortality among women due to its asymptomatic nature in early stages.\n– Kenya sees many cases diagnosed at advanced stages (III/IV)\, primarily due to non-specific symptoms and lack of screening.\n– Important to understand pelvic anatomy and tumor spread patterns for accurate diagnosis and surgical planning. \nFertility Preservation in Ovarian Cancer (Dr. Charles Muteshi) \n– Fertility-sparing surgery should be considered in selected early-stage epithelial ovarian cancers (Stage I).\n– Discussion on embryo/oocyte cryopreservation for patients undergoing gonadotoxic treatment.\n– Emphasized need for multidisciplinary counseling and prompt fertility consultations to ensure oncologic safety and reproductive potential. \nRole of PARP Inhibitors (Dr. Peter Oyiro) \n– PARP inhibitors like Olaparib offer significant benefits in BRCA-mutated and homologous recombination-deficient (HRD) ovarian cancers.\n– SOLO-1 and SOLO-2 studies demonstrated prolonged progression-free survival and delayed recurrence in both frontline and maintenance settings.\n– 7-year follow-up data show sustained benefit\, with over 48% progression-free survival in Olaparib arms.\n– Low incidence of serious adverse events\, with anemia\, fatigue\, and nausea as the most common.\n– Highlighted integration into Kenya Cancer Treatment Guidelines and importance of HRD testing.
URL:https://kesho-kenya.org/event/advanced-ovarian-cancer/
LOCATION:Virtual Event (Zoom)\, Kenya
CATEGORIES:CME 2025,Continuing Medical Education (CME)
ATTACH;FMTTYPE=image/jpeg:https://kesho-kenya.org/wp-content/uploads/2025/04/IMG-20250423-WA0000-e1745403823792.jpg
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=Africa/Nairobi:20250410T190000
DTEND;TZID=Africa/Nairobi:20250410T203000
DTSTAMP:20260423T225724
CREATED:20250407T135020Z
LAST-MODIFIED:20250622T144124Z
UID:24249-1744311600-1744317000@kesho-kenya.org
SUMMARY:Esophageal Cancer CME
DESCRIPTION:[vc_row][vc_column][vc_column_text]Esophageal Cancer CME – Experience from a Regional Cancer Centre \nModerator: Dr Tracy Irura \nSpeakers & Topics: \n\nDr Omar Abdihamid: Evolving Landscape of Esophageal Cancer Treatment\nDr Abdullahi Hadi: Optimising Diagnosis of Esophageal Cancer\nDr Mohamed Noor: Surgical Approaches to Esophageal Cancer\n\nDr. Noor Mohamed provided a historical evolution of esophageal cancer surgery from Czerny’s resection to modern minimally invasive techniques.\n– Surgical resection remains critical\, especially for early-stage and select advanced cases after neoadjuvant therapy.\n– Key considerations include thorough staging (OGD\, PET-CT\, EUS)\, patient optimization (nutrition\, glycemic control)\, and perioperative care.\n– Outcomes from global surgical databases: R0 resection rates up to 93%\, 30- and 90-day mortality rates at 2% and 4.5% respectively.\n– Challenges in Kenya include late presentation\, limited access to ICU care\, and lack of trained personnel.\n– Trials such as CROSS\, PreSANO\, and SANO are shaping modern surveillance versus resection decisions in select cases. \nDr. Omar Abdihamid – emphasized that most patients in Kenya present with locally advanced disease; male/female incidence is similar.\n– Immunotherapy has shifted paradigms: CheckMate 648 showed improved OS with nivolumab + chemotherapy or ipilimumab.\n– CROSS and ESOPEC trials guide perioperative regimens (carbo/taxol RT → surgery → nivolumab vs FLOT-based therapy).\n– Early-stage SCC may be treated with endoscopic resection if well-differentiated\, superficial\, and no lymphovascular invasion.\n– Radiotherapy regimens tailored by location: cervical tumors dose-escalated up to 60Gy; others typically 50.4Gy.\n– Garissa Cancer Centre approach includes advanced IMRT planning\, with regional data contributing to genomic and QoL research.\n– SANO trial supports non-inferiority of active surveillance post-chemoradiotherapy\, showing similar OS to surgery and better QoL.[/vc_column_text][/vc_column][/vc_row][vc_row][vc_column][/vc_column][/vc_row]
URL:https://kesho-kenya.org/event/esophageal-cancer-cme/
LOCATION:Virtual Event (Zoom)\, Kenya
CATEGORIES:CME 2025,Continuing Medical Education (CME),Symposia and Workshops
ATTACH;FMTTYPE=image/jpeg:https://kesho-kenya.org/wp-content/uploads/2025/04/IMG-20250407-WA0000-e1746480214833.jpg
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=Africa/Nairobi:20250403T190000
DTEND;TZID=Africa/Nairobi:20250403T203000
DTSTAMP:20260423T225724
CREATED:20250414T200239Z
LAST-MODIFIED:20250622T144124Z
UID:24384-1743706800-1743712200@kesho-kenya.org
SUMMARY:Head and Neck Cancer
DESCRIPTION:Moderator: Dr Angela Waweru \nSpeakers & Topics: \n\nDr Harish Nagaraj: Radiologic Imaging of Head & Neck Cancers\nDr Solomon Mutua: Role of PET/CT Scan in Head & Neck Imaging\n\nDr. Solomon Mutua emphasized the value of PET/CT in radiotherapy planning:\n– PET/CT allows for biologic imaging of tumors\, identifying hypoxic and metabolically active subvolumes.\n– Integration improves accuracy in delineating gross tumor volume (GTV)\, allowing for dose escalation while minimizing toxicity.\n– Particularly beneficial in cases with occult primaries\, equivocal CT/MRI\, and in adaptive RT strategies.\n– PET/CT-based contouring can reduce geographical misses and optimize nodal staging and treatment response.\n– Hypoxia imaging and dose painting are under investigation to further personalize radiotherapy protocols. \n 
URL:https://kesho-kenya.org/event/head-and-neck-cancer-3/
LOCATION:Virtual Event (Zoom)\, Kenya
CATEGORIES:CME 2025,Continuing Medical Education (CME)
ATTACH;FMTTYPE=image/jpeg:https://kesho-kenya.org/wp-content/uploads/2025/04/Head-Neck-Cancer-e1749669290141.jpg
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=Africa/Nairobi:20250327T190000
DTEND;TZID=Africa/Nairobi:20250327T203000
DTSTAMP:20260423T225724
CREATED:20250611T191852Z
LAST-MODIFIED:20250622T142307Z
UID:38875-1743102000-1743107400@kesho-kenya.org
SUMMARY:Management of Kidney Cancer
DESCRIPTION:Moderator: Dr Jonathan Wala \nSpeakers & Topics: \n\nDr Amina K. Habib: Optimizing Kidney Cancer Care\nDr Patrick Mbuthia: Surgical Aspects of Kidney Cancer Management\n\nDiagnosis and Evaluation \n– RCC includes clear cell\, papillary\, chromophobe\, and rare subtypes.\n– Classic triad (flank pain\, hematuria\, mass) is rare and suggests late-stage disease.\n– Paraneoplastic syndromes present in ~30% of cases.\n– Imaging: Ultrasound (cystic lesions)\, MRI/CT (staging)\, and renal function tests.\n– Renal biopsy recommended for indeterminate lesions\, small masses for surveillance\, or metastatic confirmation. \nSurgical Management \n– Partial nephrectomy preferred in localized RCC for nephron-sparing and better long-term outcomes.\n– Thrombectomy improves survival in non-metastatic RCC with IVC involvement.\n– Cytoreductive nephrectomy and metastasectomy have roles in selected metastatic cases. \n Upper Tract Urothelial Carcinoma (UTUC) \n– Represents 5–10% of urothelial cancers\, commonly presents with hematuria.\n– Risk factors: smoking\, aristolochic acid\, arsenic exposure\, Lynch syndrome.\n– Diagnostic tools: CT/MRI\, cystoscopy\, urinary cytology\, retrograde pyelography\, ureteronephroscopy. \nManagement of UTUC \n– Low-risk: Endoscopic ablation + topical chemotherapy.\n– High-risk localized: Radical nephroureterectomy + bladder cuff removal\, postoperative intravesical chemotherapy.\n– Role of lymph node dissection and neoadjuvant chemotherapy is still being defined.
URL:https://kesho-kenya.org/event/management-of-kidney-cancer/
CATEGORIES:CME 2025,Continuing Medical Education (CME)
ATTACH;FMTTYPE=image/jpeg:https://kesho-kenya.org/wp-content/uploads/2025/06/Kidney-Cancer-e1749669450937.jpg
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=Africa/Nairobi:20250320T190000
DTEND;TZID=Africa/Nairobi:20250320T203000
DTSTAMP:20260423T225724
CREATED:20250611T192311Z
LAST-MODIFIED:20250622T142307Z
UID:38878-1742497200-1742502600@kesho-kenya.org
SUMMARY:Metastatic Colorectal Cancer
DESCRIPTION:Moderator: Dr Alex Muturi \nSpeakers & Topics: \n\nProf Olusegun Alatise: Surgical & Gastroenterology Perspectives in mCRC Management\nDr Andrew Odhiambo: First‑Line Therapy in mCRC – With or Without?\n\nGlobal and African Burden of CRC \n– CRC is the third most diagnosed cancer globally with an increasing burden in LMICs.\n– African patients show distinct molecular and clinical features\, including poor survival outcomes. \nPrinciples of Metastatic CRC Management \n– Multidisciplinary approach is essential; cure remains possible in select patients.\n– Surgery for metastasis should be guided by tumor biology\, technical feasibility\, and patient fitness.\n– Synchronous vs metachronous disease influences treatment sequencing. \nImaging and Surgical Considerations \n– Triphasic CT\, MRI with contrast\, and PET scans are standard.\n– Resectability is based on liver function and margin clearance\, not number/size of lesions. \nSurgical and Interventional Therapies \n– Options: surgical resection\, ablation\, HAIP chemotherapy\, two-stage hepatectomy\, ALPPS\, SIRT.\n– Preoperative chemotherapy helps with tumor downsizing and biology assessment but may impair liver function. \nGenetic and Prognostic Scoring \n– CRS\, GAME\, MRS\, and MSI/BRAF/TP53 profiles aid in stratifying patients.\n– Even high-risk patients can achieve long-term survival with careful selection. \nNewer Modalities \n– Thermal ablation is effective for small (<3cm) liver lesions.\n– Liver transplant is under investigation for select liver-only\, unresectable CRC. \nPeritoneal Carcinomatosis \n– Cytoreductive surgery + HIPEC has survival benefits in low PCI scores.\n– PRODIGE 7\, COLOPEC\, and PROPHYLOCHIP trials show limited benefit of prophylactic HIPEC \nConclusion \n– Metastatic CRC is treatable; coordinated\, case-specific care improves survival.\n– Early detection and healthcare system strengthening in Africa are vital.
URL:https://kesho-kenya.org/event/metastatic-colorectal-cancer-3/
CATEGORIES:CME 2025,Continuing Medical Education (CME)
ATTACH;FMTTYPE=image/jpeg:https://kesho-kenya.org/wp-content/uploads/2025/06/Metastatic-Colorectal-Cancer-e1749669731932.jpg
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=Africa/Nairobi:20250313T190000
DTEND;TZID=Africa/Nairobi:20250313T203000
DTSTAMP:20260423T225724
CREATED:20250611T192853Z
LAST-MODIFIED:20250622T142307Z
UID:38882-1741892400-1741897800@kesho-kenya.org
SUMMARY:Women in Oncology
DESCRIPTION:International Women’s Day: Women in Oncology \nModerator: Ms Benda Kithaka \nSpeakers & Topics: \n\nDr Catherine Nyongesa: Women in Leadership\nDr Khadija Warfa: Challenges Faced by Women in Oncology\nDr Gladwell Kiarie: Women in Oncology – How to Step Up the Game!\nProf Nazik Hammad: Harnessing Solidarity Between African Women in Oncology\n\nDr. Warfa discussed the multifaceted challenges faced by female oncologists in Africa\, including work-life imbalance\, gender-based microaggressions\, and structural sexism. She emphasized how family responsibilities\, limited mentorship\, and hierarchical work environments hinder progress. Solutions include flexible work arrangements\, inclusive leadership\, bias training\, and equitable opportunities for advancement. She also highlighted the importance of accurate gender representation in medical discourse and the superior clinical outcomes observed among female physicians. \nDr. Nyongesa focused on leadership development for women in oncology\, identifying critical attributes such as emotional intelligence\, vision\, resilience\, and effective communication. She encouraged mentorship\, strategic positioning\, and self-awareness. The presentation promoted intentional leadership development and emphasized that empowered women are key to empowering entire communities. \nDr. Kiarie highlighted systemic gender disparities in oncology\, such as underrepresentation in leadership\, editorial boards\, and conferences. She emphasized key challenges including lack of mentorship\, pay gaps\, burnout\, and societal biases. Proposed solutions included implementing mentorship and sponsorship programs\, advocating for inclusive policies\, prioritizing self-care\, and establishing supportive networks. She stressed the importance of visibility\, advocacy\, and proactive self-promotion for career progression
URL:https://kesho-kenya.org/event/women-in-oncology/
CATEGORIES:CME 2025,Continuing Medical Education (CME)
ATTACH;FMTTYPE=image/png:https://kesho-kenya.org/wp-content/uploads/2025/06/Women-in-Oncology.png
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=Africa/Nairobi:20250306T190000
DTEND;TZID=Africa/Nairobi:20250306T203000
DTSTAMP:20260423T225724
CREATED:20250611T193255Z
LAST-MODIFIED:20250622T142307Z
UID:38887-1741287600-1741293000@kesho-kenya.org
SUMMARY:Updates in Myeloma Management
DESCRIPTION:Moderator: Dr Angela Mcligieyo \nSpeakers & Topics: \n\nDr M. B. Agarwal: Front‑line Therapy Trends\nDr Rohini Radia: Transplant‑Eligible vs Ineligible Patients\nDr M. D. Maina: Evidence‑Based Maintenance\nDr Boniface Githae: Contemporary Relapse Strategies\n\nDr. Maina addressed Smoldering Multiple Myeloma (SMM)\, emphasizing risk stratification to predict progression to active myeloma. The 2/20/20 IMWG model (based on FLC ratio and bone marrow plasma cell %)\, and the Spanish model using immunoparesis and plasma cell phenotyping\, were presented. Patients with ≥2 risk factors have a 50% chance of progression within 2 years. Ongoing efforts to integrate clinical and genomic risk markers aim to guide early therapeutic interventions. \nDr. Radia emphasized that autologous stem cell transplant (ASCT) remains the standard of care for transplant-eligible patients after induction chemotherapy. Key findings from major trials (IFM2009\, EMN02/H095) showed that ASCT improves progression-free survival (PFS) but does not significantly impact overall survival (OS). Post-ASCT maintenance therapy with lenalidomide improves PFS across all cytogenetic risk groups. CAR-T cell therapy and bispecific antibodies like Teclistamab and Elranatamab show promise in relapsed/refractory multiple myeloma (RRMM)\, offering new options with high response rates\, albeit with logistical and toxicity concerns. Kenyan real-world data shows promising survival outcomes with ASCT. \nDr. Githaiga presented practical approaches to diagnosis\, transplant eligibility\, and treatment selection. Diagnostic workups include comprehensive labs and bone marrow studies. For transplant-eligible patients\, quadruplet regimens like Dara-VRd followed by ASCT and lenalidomide maintenance are preferred. In high-risk cases\, bortezomib-based maintenance is advised. In non-transplant candidates\, extended triplet regimens followed by maintenance were recommended. He also highlighted Kenyan drug cost considerations and the importance of supportive care with antivirals\, antibiotics\, and bone-targeting agents.
URL:https://kesho-kenya.org/event/updates-in-myeloma-management/
CATEGORIES:CME 2025,Continuing Medical Education (CME)
ATTACH;FMTTYPE=image/jpeg:https://kesho-kenya.org/wp-content/uploads/2025/06/Updates-in-Myeloma-Management-e1749726883405.jpg
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=Africa/Nairobi:20250227T190000
DTEND;TZID=Africa/Nairobi:20250227T203000
DTSTAMP:20260423T225724
CREATED:20250611T193814Z
LAST-MODIFIED:20250622T142307Z
UID:38891-1740682800-1740688200@kesho-kenya.org
SUMMARY:AML: A Local Perspective
DESCRIPTION:Moderator: Prof Abinya \nSpeakers & Topics: \n\nDr Anne Mwirigi: Local Experience at a Tertiary Hospital\nDr Rohini Radia: The Role of Cytogenetics & Molecular Markers\nDr Peter Oyiro: Genomic Classification & Medical Oncology Pathways\nDr Beatrice Jepngetich: Panelist Discussion\nDr Mercy Gatua: Panelist Discussion\n\n Summary \nAML is genetically heterogeneous\, with most patients having multiple driver mutations.\n– WHO 2022 classification emphasizes genetic abnormalities over morphology or blast count.\n– Defining cytogenetic lesions like inv(16) or t(8;21) now suffice for diagnosis even with <20% blasts. \nDiagnostic Work-Up \n– FBC and peripheral blood smear\n– Bone marrow aspirate: morphology\, flow cytometry\, LAIP for MRD\n– Cytogenetics: Karyotyping and FISH\n– Next-Generation Sequencing (NGS): TP53\, NPM1\, etc.\n– Bone marrow trephine with immunocytochemistry. \nClinical Implications \n– Risk stratification through cytogenetics + molecular testing informs prognosis and treatment plan.\n– Favorable-risk patients may receive chemotherapy; adverse-risk patients considered for early allogeneic transplant.\n– MRD monitoring increasingly guides transplant decisions. \nTakeaways \n– AML is curable in a subset with intensive chemo + risk-adapted approach.\n– Precision oncology depends on accessible molecular diagnostics.\n– LMICs face challenges integrating NGS-based stratification.\n– Hypomethylating agents + Venetoclax offer promise in select patient groups.
URL:https://kesho-kenya.org/event/aml-a-local-perspective/
LOCATION:Aga Khan University\, Nairobi
CATEGORIES:CME 2025,Continuing Medical Education (CME)
ATTACH;FMTTYPE=image/jpeg:https://kesho-kenya.org/wp-content/uploads/2025/06/A-Local-Perspective-e1749671173338.jpg
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=Africa/Nairobi:20250220T190000
DTEND;TZID=Africa/Nairobi:20250220T193000
DTSTAMP:20260423T225724
CREATED:20250217T194237Z
LAST-MODIFIED:20250622T142307Z
UID:38895-1740078000-1740079800@kesho-kenya.org
SUMMARY:International Childhood Cancer Day
DESCRIPTION:Moderator: Dr Alice Gichemi \nSpeaker & Topic: \nDr Terry Vik: Flow Cytometry for Rapid Diagnosis of Lymphoid Malignancies in Children & Teenagers \nGlobal Context \n– Childhood cancer cure rates: 80% in high-income countries\, ~30% in LMICs.\n– Barriers: delayed diagnosis\, treatment abandonment\, limited diagnostic access.\n– WHO/SIOP target: Double survival and save 1 million children by 2030. \n Leukemia Diagnosis in Kenya \n– Common signs: Pallor\, Pyrexia\, Purpura\, Pain (bony).\n– First-line tests: CBC and peripheral smear.\n– Many children present with Hgb < 7.0 — indicates late presentation. \nRole of Flow Cytometry \n– Globally standard for classifying ALL/AML.\n– In Kenya\, it’s reducing time-to-treatment\, especially in Burkitt Lymphoma (from 13.6 to 10.5 days).\n– Used on both bone marrow and peripheral blood samples for early diagnosis. \n Clinical Pilot Highlights \n– MTRH pilot expanding to 100 patients in 2026.\n– Focus: Feasibility of flow cytometry in peripheral blood diagnostics.\n– Goal: Develop scalable and SHIF/NHIF-coverable diagnostic methods. \nKey Clinical Takeaways \n– Recognize early signs of leukemia using the 4 P’s.\n– Flow cytometry is feasible and impactful in Kenya.\n– Early diagnosis can save lives — integration into local protocols is critical.
URL:https://kesho-kenya.org/event/international-childhood-cancer-day/
CATEGORIES:CME 2025,Continuing Medical Education (CME)
ATTACH;FMTTYPE=image/jpeg:https://kesho-kenya.org/wp-content/uploads/2025/06/International-Childhood-Cancer-Day-e1749670857260.jpg
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=Africa/Nairobi:20250206T190000
DTEND;TZID=Africa/Nairobi:20250206T203000
DTSTAMP:20260423T225724
CREATED:20250203T194848Z
LAST-MODIFIED:20250623T131746Z
UID:38898-1738868400-1738873800@kesho-kenya.org
SUMMARY:United for Cancer Prevention
DESCRIPTION:United for Cancer Prevention – People‑Centered Approaches in Healthcare\n\nModerator: Dr Douglas Nyandika\n\nSpeakers & Topics:\n\n 	Carol Wakesa: Community‑Led Prevention Strategies\n 	Dr Joan‑Paula Boit: Risk‑Reduction in Gynaecologic Cancers\n 	Dr Jerome Katamba: Behavioural Science & Cancer Prevention\n 	Dr Francis Makokha: The Socio‑Economic Determinants of Prevention Uptake\n 	Mr David Makumi: Building Survivor‑Led Advocacy Networks
URL:https://kesho-kenya.org/event/united-for-cancer-prevention/
CATEGORIES:CME 2025,Continuing Medical Education (CME)
ATTACH;FMTTYPE=image/jpeg:https://kesho-kenya.org/wp-content/uploads/2025/06/United-for-Cancer-Prevention-e1749671294368.jpg
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=Africa/Nairobi:20250123T190000
DTEND;TZID=Africa/Nairobi:20250123T203000
DTSTAMP:20260423T225724
CREATED:20250611T183601Z
LAST-MODIFIED:20250622T142307Z
UID:38855-1737658800-1737664200@kesho-kenya.org
SUMMARY:Cervical Cancer Care
DESCRIPTION:Advanced Ovarian Cancer \nModerator: Prof Rose J. Kosgei \nSpeakers & Topics: \n\nProf Omenge Orang’o: Management of Epithelial Ovarian Cancer\nDr Peter Oyiro: PARP Inhibitors in Ovarian Cancer\nDr Charles Muteshi: Fertility Preservation in Ovarian Cancer\n\nEpidemiology and Diagnosis (Prof. Omenge Oran’go) \n– Ovarian cancer remains a significant cause of cancer mortality among women due to its asymptomatic nature in early stages.\n– Kenya sees many cases diagnosed at advanced stages (III/IV)\, primarily due to non-specific symptoms and lack of screening.\n– Important to understand pelvic anatomy and tumor spread patterns for accurate diagnosis and surgical planning. \nFertility Preservation in Ovarian Cancer (Dr. Charles Muteshi) \n– Fertility-sparing surgery should be considered in selected early-stage epithelial ovarian cancers (Stage I).\n– Discussion on embryo/oocyte cryopreservation for patients undergoing gonadotoxic treatment.\n– Emphasized need for multidisciplinary counseling and prompt fertility consultations to ensure oncologic safety and reproductive potential. \nRole of PARP Inhibitors (Dr. Peter Oyiro) \n– PARP inhibitors like Olaparib offer significant benefits in BRCA-mutated and homologous recombination-deficient (HRD) ovarian cancers.\n– SOLO-1 and SOLO-2 studies demonstrated prolonged progression-free survival and delayed recurrence in both frontline and maintenance settings.\n– 7-year follow-up data show sustained benefit\, with over 48% progression-free survival in Olaparib arms.\n– Low incidence of serious adverse events\, with anemia\, fatigue\, and nausea as the most common.\n– Highlighted integration into Kenya Cancer Treatment Guidelines and importance of HRD testing.
URL:https://kesho-kenya.org/event/cervical-cancer-care/
CATEGORIES:CME 2025,Continuing Medical Education (CME)
ATTACH;FMTTYPE=image/jpeg:https://kesho-kenya.org/wp-content/uploads/2025/06/Cervical-Cancer-scaled-e1749667096838.jpg
END:VEVENT
END:VCALENDAR